Document:

<PAGE>   1
Certain material (indicated by an asterisk) has been omitted from this document
pursuant to a request for confidential treatment.  The omitted material has been
filed separately with the Securities and Exchange Commission.

                                                                    EXHIBIT 10.1

                   FIRST AMENDMENT TO CO-PROMOTION AGREEMENT

        THIS FIRST AMENDMENT TO THE CO-PROMOTION AGREEMENT dated May 27, 1999,
by and between ORTHO-MCNEIL PHARMACEUTICAL, INC., a Delaware corporation
("ORTHO"), and WOMEN FIRST HEALTHCARE, INC., a Delaware corporation ("WFHC")
hereinafter ("CO-PROMOTION AGREEMENT") is made as of March 31, 2000.

                                    RECITALS

        WHEREAS, ORTHO and WFHC entered into a CO-PROMOTION AGREEMENT to
Co-Promote certain Products which are identified in the CO-PROMOTION AGREEMENT
as ORTHO-PREFEST(TM), ORTHO TRI-CYCLEN(R), and ***.

        WHEREAS, the parties have decided to restructure the CO-PROMOTION
AGREEMENT so as to eliminate from the CO-PROMOTION AGREEMENT the right of WFHC
to Co-Promote ORTHO Oral Contraceptive Products, particularly ORTHO
TRI-CYCLEN(R) and ***.

        WHEREAS, ORTHO and WFHC wish to continue the Co-Promotion of
ORTHO-PREFEST(TM) pursuant to the terms of the CO-PROMOTION AGREEMENT as amended
herein.

        NOW, THEREFORE, in consideration of the covenants and promises contained
in this Agreement, ORTHO and WFHC agree as follows:

* Certain material (indicated by an asterisk) has been omitted from this
  document pursuant to a request for confidential treatment.  The omitted
  material has been filed separately with the Securities and Exchange
  Commission.
<PAGE>   2

                          AMENDED TERMS AND CONDITIONS

1. For the purposes of this Amendment, the defined terms in the CO-PROMOTION
AGREEMENT shall have the same meaning when used herein.

2. In the CO-PROMOTION AGREEMENT, all provisions relating to the Oral
Contraceptive Products ORTHO TRI-CYCLEN(R) and *** including but
not limited to WFHC's rights and obligations to co-promote such Products shall
be eliminated from the CO-PROMOTION AGREEMENT. This also includes any
compensation provisions relating to such Products. Accordingly, the definition
of Product is amended to mean ORTHO-PREFEST(TM). Notwithstanding the foregoing,
or any other provision of this Amendment to the contrary, each party's
obligations under Article 10 of the CO-PROMOTION AGREEMENT shall remain in full
force and effect with respect to ORTHO TRI-CYCLEN(R) AND ***.

3. While it is understood and agreed that pursuant to the terms of the
CO-PROMOTION AGREEMENT, prior to this amendment thereto, WFHC is not entitled to
any compensation for the Details made in connection with ORTHO TRI-CYCLEN(R),
the parties pursuant to this Amendment have agreed to compensation for the
actual Details for ORTHO TRI-CYCLEN(R) made for the third and fourth calendar
quarters of 1999 and the first calendar quarter of 2000. The agreed upon
compensation for such Details is one million five hundred thousand dollars
($1,500,000) payable prior to May 15, 2000. Compensation for Co-Promotion of
ORTHO-PREFEST(TM) shall remain as recited in the CO-PROMOTION AGREEMENT.

4. Paragraph 2.3 (a) in the CO-PROMOTION AGREEMENT is deleted in its entirety
and replaced with the following new paragraph 2.3(a):

        "2.3 (a) WFHC shall not market, promote, distribute or sell any
        Contraceptive Product or HRT Product indicated and approved for human
        consumption in the Territory, other than ORTHO-EST(R) and
        ORTHO-PREFEST(TM) during the Term

* Certain material (indicated by an asterisk) has been omitted from this
  document pursuant to a request for confidential treatment.  The omitted
  material has been filed separately with the Securities and Exchange
  Commission.
<PAGE>   3
        and for a period of three months thereafter; provided, however, that
        WFHC may promote an estrogen only patch product or another product that
        is other than a Contraceptive Product or HRT Product through the WFHC
        Sales Force *** during a Detail if such product(s) is defined in the
        call plan for its sales representatives and such call plan is not
        changed more than four times per year. WFHC may, however, promote such
        estrogen patch product or any Contraceptive Product through a Sales
        Force that is independent from the WFHC Sales Force at anytime and in
        any position it so desires. Notwithstanding the foregoing, the three
        month period after the Term shall not exist if the Term is shortened as
        a result of termination under Section 13.4(a) (i), (ii) and (iv), and
        (b), (i) and (ii) and Section 13.5 in the event of termination by WFHC
        as a result of ORTHO's breach."

5. In consideration for the restrictions recited in Section 4 of this Amendment
regarding the promotion of Contraceptive and HRT Products, ORTHO agrees to pay
WFHC five hundred thousand dollars ($500,000) payable prior to May 15, 2000.

6. Paragraph 4.3(b) in the CO-PROMOTION AGREEMENT is deleted in its entirety and
replaced with the following new paragraph 4.3(b):

        "4.3(b)Assuming 150 representatives, the number of Details for 2000
        shall be ***, with *** Details required during the first calendar
        quarter of 2000 and *** Details required during each of the second
        through fourth calendar quarters of 2000; and the number of Details for
        2001 through 2002 shall be ***."

7. Paragraph 4.3 (c) in the CO-PROMOTION AGREEMENT is deleted in its entirety
and replaced with the following new paragraph 4.3 (c):

        " 4.3. (c) On each Detail, WFHC agrees to present the Sales Message on
        ORTHO-PREFEST(TM) in the *** to the Prescribing
        Physicians and present no

* Certain material (indicated by an asterisk) has been omitted from this
  document pursuant to a request for confidential treatment.  The omitted
  material has been filed separately with the Securities and Exchange
  Commission.
<PAGE>   4

        more than *** other products on any single call in the ***."

8. All other terms of the CO-PROMOTION AGREEMENT shall remain as is to the
extent they apply solely toward the co-promotion of ORTHO-PREFEST(TM).

9. ORTHO may distribute only such quantities of promotional materials for ORTHO
TRI-CYCLEN(R) which bear WFHC's Trademarks and logos as ORTHO has in stock as of
the date of this Amendment.

* Certain material (indicated by an asterisk) has been omitted from this
  document pursuant to a request for confidential treatment.  The omitted
  material has been filed separately with the Securities and Exchange
  Commission.
<PAGE>   5

        IN WITNESS WHEREOF, the Parties have caused this Amendment to be
executed by their respective duly authorized officers or representatives as of
the day and year first written above.

ORTHO-MCNEIL                                WOMEN FIRST HEALTHCARE, INC.
PHARMACEUTICAL, INC.

By:  /S/ ROBERT G. SAVAGE                   By:  /s/ DAVID F. HALE
   -----------------------------               ---------------------------------

President                                   President

Date:  MAY 8, 2000                          Date:  MAY 3, 2000
     ---------------------------                 -------------------------------<PAGE>   1
Certain material (indicated by an asterisk) has been omitted from this document
pursuant to a request for confidential treatment.  The omitted material has been
filed separately with the Securities and Exchange Commission.

                                                                    EXHIBIT 10.2

                             COPROMOTION AGREEMENT

            This Agreement ("Amendment No. 1") is made by and between
BRISTOL-MYERS SQUIBB U.S. PHARMACEUTICALS GROUP, a division of E.R. SQUIBB &
SONS, INC., a Delaware corporation, having a place of business at 777 Scudders
Mill Road, Plainsboro, New Jersey 08536 ("BMS"), and WOMEN FIRST HEALTHCARE,
INC., a Delaware corporation, maintaining its principal business offices at
12220 El Camino Real, Suite 400 San Diego, California 92130 ("WFHC").

                              W I T N E S S E T H:

            WHEREAS, effective March 1, 1999, BMS and WFHC entered into a
copromotion agreement for BMS' product Pravachol(R) under which WFHC would
promote such product to OB/GYNs in the United States (said agreement, referred
to herein as the "Copromotion Agreement"); and

            WHEREAS, the parties desire to amend such Copromotion Agreement.

            NOW, THEREFORE, in consideration of the mutual covenants herein set
forth, and intending to be legally bound hereby, the parties hereto agree as
follows:

1.    The third "WHEREAS" clause and the definition of "Covered Physician" are
      amended to delete the following phrase:

            "and to those primary care physicians whose primary practices are
      in the field of OB/GYN medical care and who are designated as an OB/GYN
      on BMS' internal tracking databases"

2.    In Sections 7(c) and 8(c), the reference to "Section 6(d)" therein shall
      be changed to "Section 7(d)".

3.    Articles 11, 12 and 13 of the Copromotion Agreement are revised to read
      as set forth in Attachment 1 to this Amendment No. 1.

4.    Exhibit A to the Copromotion Agreement is revised in its entirety to read
      as set forth in Attachment 2 to this Amendment No. 1.

5.    The following is added to the end of the second paragraph of Section 8(a):

      "Upon request, WFHC will review with BMS WFHC's procedures for Product
      samples accountability and control and will incorporate any reasonable
      recommendations made by BMS to improve accountability and control.
      Further, WFHC will provide BMS with a monthly electronic report, within
      forty-five (45) days after the close of an Agreement Quarter, setting
      forth ME number, Territory number, and the date of disbursement and
      sample units disbursed (by strength) in such preceding month. WFHC agrees
      that Product samples distributed by its Sales Force in any Agreement
      Quarter (out of the Product samples provided to it for an Agreement Year)
      shall be in such quantities as correspond in all material respects with
      the distribution of Baseline Quarterly Prescriptions (as compared to the
      Baseline Agreement Year Prescriptions) for such Agreement

                                       1
<PAGE>   2

     Year."

6.   Except where otherwise specifically defined herein, any capitalized terms
     used in this Amendment No. 1 shall have the meaning ascribed to such term
     in the Copromotion Agreement.

7.   The effective date of the amendments set forth in paragraphs 1, 2 and 3 of
     this Amendment No. 1 shall be effective as of April 1, 2000. The effective
     date of the amendment set forth in paragraph 4 of this Amendment No. 1
     shall be effective as of April 1, 1999.

8.   BMS represents and warrants to WFHC that (i) the execution, delivery and
     performance of this Amendment No. 1 by BMS does not conflict with, or
     constitute a breach of or under, any order, judgment, agreement or
     instrument to which BMS is a party; and (ii) the execution, delivery and
     performance of this Agreement by BMS does not require the consent of any
     person or the authorization of (by notice or otherwise) any governmental
     or regulatory authority. WFHC represents and warrants to BMS that (i) the
     execution, delivery and performance of this Agreement by WFHC does not
     conflict with, or constitute a breach of or under, any order, judgment,
     agreement or instrument to which WFHC is a party; and (ii) the execution,
     delivery and performance of this Agreement by WFHC does not require the
     consent of any person or the authorization of (by notice or otherwise) any
     governmental or regulatory authority.

9.   Except as herein modified, the parties confirm that the Copromotion
     Agreement remains in full force and effect.

                               ******************

     IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement
in multiple counterparts through their duly authorized representatives.

BRISTOL-MYERS SQUIBB U.S.                    WOMEN FIRST HEALTHCARE, INC.
PHARMACEUTICALS GROUP

By:  /s/ KRISTINE PETERSON  5-11-00          By: /s/ DAVID F. HALE
   ------------------------------------         --------------------------------
   Name:  Kristine Peterson                     Name:  David Hale
   Title: Senior Vice-President                 Title: President
          Metabolics Diseases Marketing

                                       2

<PAGE>   3

ATTACHMENT 1 to AMENDMENT NO. 1

The parties agree to replace Articles 11, 12 and 13 of the Copromotion
Agreement with the following:

"11. COPROMOTION COMPENSATION.

          (a) As compensation for services rendered by WFHC during the
Copromotion Term and its agreements hereunder, BMS shall pay to WFHC a fee
("Performance Fee") with respect to each Agreement Quarter during the term
hereof *** of those Net Sales Attributable to Covered
Physicians that are in excess of the Baseline Quarterly Sales Attributable to
Covered Physicians for such Agreement Quarter.

          (b) For purposes of this Agreement:

     "Average Selling Price per Prescription" means, for any Agreement Quarter,
the Total Net Sales of the Product in the Territory for the applicable period
from prescriptions written by all physicians of all specialties and practices,
divided by the total number of retail (TRX) and mail order prescriptions (TRX)
for the Product that are written or ordered in such applicable period by Covered
and Non-Covered Physicians. The number of retail (TRX) prescriptions shall be
determined by the National Prescriptions Audit Plus: Prescriber Specialty Report
as issued by IMS America. The number of mail order prescriptions for a given
Agreement Quarter shall be deemed equal to *** of the number of retail
prescriptions determined for such Agreement Quarter (with the Average Selling
Price for mail order prescriptions to be adjusted (i.e., trued up) to be
equivalent with the number of tablets per prescription on a retail basis).

     "Baseline Quarterly Sales Attributable to Covered Physicians" for each
Agreement Quarter shall mean the product of: (i) the Baseline Quarterly
Prescriptions for such Agreement Quarter, multiplied by (ii) the Average
Selling Price per Prescription for such Agreement Quarter.

     "Baseline Agreement Year Prescriptions" for an Agreement Year means:

     (i)    For the first Agreement Year, ***  Covered Physician Prescriptions.

     (ii)   For the second Agreement Year, *** Covered Physician Prescriptions.

     (iii)  For the third Agreement Year, the sum of (1) *** Covered Physician
            Prescriptions, plus (2) a number that is the product of (A) ***
            Covered Physician Prescriptions ***

                                       3

* Certain material (indicated by an asterisk) has been omitted from this
  document pursuant to a request for confidential treatment.  The omitted
  material has been filed separately with the Securities and Exchange
  Commission.
<PAGE>   4
     "Baseline Quarterly Prescriptions" shall mean:

     (i)   For the first Agreement Year,

           -  *** Covered Physician Prescriptions for 3/1/99-6/30/99;
           -  *** Covered Physician Prescriptions for 7/1/99-9/30/99;
           -  *** Covered Physician Prescriptions for 10/1/99-12/31/99;
           -  *** Covered Physician Prescriptions for 1/1/00-3/31/00.

     (ii)  For the second Agreement Year,

           -  *** Covered Physician Prescriptions for 4/1/00-6/30/00;
           -  *** Covered Physician Prescriptions for 7/1/00-9/30/00;
           -  *** Covered Physician Prescriptions for 10/1/00-12/31/00;
           -  *** Covered Physician Prescriptions for 1/1/01-3/31/01.

     (iii) For each Agreement Quarter in the third Agreement Year, one-fourth of
           the Baseline Agreement Year Prescriptions for the Third Agreement
           Year.

     "Covered Physician Prescriptions" shall equal the sum of the number of
retail prescriptions (TRX) for the Product that are written or ordered by
Covered Physicians as determined by the National Prescriptions Audit Plus:
Prescriber Specialty Report as issued by IMS America, plus the number of mail
order prescriptions for the Product. The number of mail order prescriptions for
a given Agreement Quarter shall be deemed equal to *** of the number of retail
prescriptions determined for such Agreement Quarter (with the Average Selling
Price for mail order prescriptions to be adjusted (i.e., trued up) to be
equivalent with the number of tablets per prescription on a retail basis).

     "Net Sales Attributable to Covered Physicians" means, for any Agreement
Quarter, a number equal to the product of (i) the number of Covered Physician
Prescriptions for the applicable period, multiplied by (ii) the Average Selling
Price per Prescription for such applicable period.

          (c)  (i) BMS shall, subject to section 11(d) below, pay to WFHC, with
respect to each Agreement Quarter during the term of this Agreement, ***.

               (ii) WFHC shall, subject to section 11(d) below, pay to BMS,
with respect to each Agreement Quarter during the term of this Agreement, ***.

          (d)  (i) Compensation due WFHC under this Article 11 above shall be

                                       4

* Certain material (indicated by an asterisk) has been omitted from this
  document pursuant to a request for confidential treatment.  The omitted
  material has been filed separately with the Securities and Exchange
  Commission.
<PAGE>   5
calculated and paid within 60 days after the end of each Agreement Quarter
during the Copromotion Term, in accordance with Sections 11(a)-(c) and 12
hereof. Any payments not made when due under Sections 11(a)-(c) bear interest at
the rate of *** per annum (or the highest rate permitted by applicable law,
whichever is the lower) on the unpaid balance from the date due until paid in
full.

                        (ii)  BMS shall endeavor to provide to WFHC the
calculation of any amount due BMS under Section 11(c)(ii) within sixty (60)
days after the end of each Agreement Quarter in accordance with Sections
11(a)-(c) and Article 12 hereof. WFHC shall make the applicable payment due BMS
on the later of the thirtieth (30th) day after receipt of the calculation from
BMS or the sixtieth day (60th) following the end of the Agreement Quarter for
which the calculation was made. Payments not made when due shall bear interest
at the rate of *** per annum (or the highest rate permitted by
applicable law, whichever is the lower) on the unpaid balance from the date due
until paid in full.

                  (e)   In addition to compensation received during the
Copromotion Term, WFHC shall receive residual compensation ("Residual
Compensation") during the twelve (12) month period following expiration or early
termination of the Copromotion Term (the "Residual Period") equal in the
aggregate to *** of the compensation due by BMS to it for the Agreement Year
immediately preceding termination, but only where:

      (A)   (i)   This Agreement has expired in accordance with its terms at
                  the end of the term provided for hereunder (or such longer
                  term as this Agreement may be extended by mutual written
                  consent);

            (ii)  WFHC has terminated this Agreement prior to expiration in
                  accordance with section 13(b)(ii) hereof; or

            (iii) BMS has terminated this Agreement pursuant to section 13(d)
                  hereof; and

      (B)   WFHC complies with its obligations under Sections 3(e), 10, 14, 15,
            and 19 hereof.

Termination of this Agreement for any reason other than the above events shall
not trigger any Residual Compensation due WFHC. Such Residual Compensation
payment shall be made by BMS in four (4) equal quarterly installments, each
installment to be made as of the end of each Agreement Quarter in the Residual
Period.

12.         PAYMENTS AND REPORTING.

                  (a)   BMS shall furnish WFHC, within 60 days after the end of
each Agreement Quarter, a report setting forth in reasonable detail the
calculation of Net Sales Attributable to Covered Physicians for such Agreement
Quarter, and the calculation of WFHC's compensation under Section 11 with
respect to such period.

                  (b)   All payments to a party under this Agreement shall be
made by wire transfer in immediately available funds in legal currency of the
United States and shall be delivered to the account of such party designated by
it in writing from time to time.

                                       5

* Certain material (indicated by an asterisk) has been omitted from this
  document pursuant to a request for confidential treatment.  The omitted
  material has been filed separately with the Securities and Exchange
  Commission.
<PAGE>   6
            (c)   The parties will maintain complete and accurate books and
records in sufficient detail to enable verification of the detail call activity
of WFHC, the Net Sales attributable to Covered Physicians and the basis for
calculating the compensation paid by BMS to WFHC hereunder. Either party may
demand an audit of the other party's relevant books and records in order to
verify the other's reports on the aforesaid matters. Upon reasonable prior
notice to the party to be studied, the independent public accountants of the
other party shall have access to the relevant books and records of the party to
be audited in order to conduct a review or audit thereof. Such access shall be
available during normal business hours not more than once each calendar year
during the Copromotion Term and only until two years after the relevant period
in question. The accountants shall be entitled to report its conclusions and
calculations to the party requesting the audit, except that in no event shall
the accountants disclose the names of customers of either party or the prices,
discounts, rebates, or other terms of sale charged by BMS for the Product.

            The party requesting the audit shall bear the full cost of the
performance of any such audit except as hereinafter set forth. If, as a result
of any inspection of the books and records of BMS, it is shown that BMS'
payments to WFHC under this Agreement were less than the amount which should
have been paid, then BMS shall make all payments required to be made to
eliminate any discrepancy revealed by said inspection within 30 days after
WFHC's demand therefor. If, as a result of any inspection of the books and
records of WFHC, it is shown that BMS' reimbursements for costs associated with
Funded Activities to WFHC under this Agreement were more than the amount which
should have been paid, then WFHC shall reimburse BMS for the discrepancy
revealed by said inspection within 30 days after BMS' demand therefor.
Furthermore, if the payments were less than the amount which should have been
paid by an amount in excess of five percent (5%) of the payments actually made
during the period in question, the party responsible for the discrepancy shall
also reimburse the auditing party for its out-of-pocket costs of such
inspection.

13.   COPROMOTION TERM AND TERMINATION.

            (a)   The Copromotion Term shall be for three (3) years and shall
begin effective March 1, 1999 and shall end on March 31, 2002, unless
terminated earlier in accordance with Section 13(b), 13(c) or 13(d) below or
unless extended by the parties' mutual agreement in accordance with Section
13(e) below (the "Copromotion Term").

            (b)   WFHC may terminate the Copromotion Term:

      (i)   at any time, without cause, effective as of the end of an Agreement
            Year, upon written notice to BMS given not less than sixty (60)
            days' prior to the end of such Agreement Year. During such notice
            period, WFHC shall continue to fulfill its obligations under this
            Agreement; or

      (ii)  immediately upon written notice of termination given to BMS, if BMS
            has breached a material obligation or duty under this Agreement
            that is continuing thirty (30) days after WFHC has advised BMS in
            writing of the nature of said breach.

            (c)   BMS may terminate the Copromotion Term upon the occurrence of
any of the following:

                                       6
<PAGE>   7
     (i)   Upon sixty (60) days' prior written notice to WFHC, if:

           (A) Covered Physician Prescriptions for the First Agreement Year do
               not exceed *** Covered Physician Prescriptions for such Agreement
               Year, or if Covered Physician Prescriptions for the Second
               Agreement Year do not exceed *** Covered Physician Prescriptions
               for such Agreement Year, or if Covered Physician Prescriptions
               for the Third Agreement Year do not exceed *** Covered Physician
               Prescriptions for such Agreement Year, or

           (B) during the second or third Agreement Years, Aggregate Covered
               Physician Prescriptions for each Agreement Quarter ending any two
               (2) consecutive Agreement Quarters during either such Agreement
               Years do not exceed the sum of the Baseline Quarterly
               Prescriptions for such two Agreement Quarters; or

     (ii)  Upon written notice to WFHC, if BMS has permanently ceased
           manufacturing and marketing the Product because of a significant
           safety problem related to the Product; or

     (iii) BMS may terminate the Copromotion Term immediately upon written
           notice of termination given to WFHC, if WFHC has breached a material
           obligation or duty under this Agreement that is continuing 30 days
           after BMS has advised WFHC in writing of the nature of the breach or
           default; or

     (iv)  BMS may terminate the Copromotion Term immediately upon written
           notice of termination given to WFHC, if, if WFHC makes any
           inaccurate or misleading statement or public announcement with
           respect to the promotion or approved labeling for the Product,
           except where such statement or announcement was approved in writing
           by BMS in accordance with this Agreement; or

           (d) If during the Copromotion Term WFHC experiences a "change in
control", WFHC will promptly notify BMS in writing of same, and BMS shall be
entitled at any time within one hundred twenty (120) days after receipt of such
notification, in the exercise of its sole and absolute discretion, upon 90 days
written notice to WFHC, to terminate the Copromotion Term. For purposes of this
Agreement, the term "change in control" shall mean any sale of voting
securities or sale of assets (whether by sale, merger, consolidation, share
exchange, or otherwise) which, directly or indirectly , (i) transfers over 50%
of the assets of WFHC relating to the Product to any Person other than an
Affiliate of WFHC, or (ii) results in any Person (other than an Affiliate of
WFHC existing as of the Effective Date or a financial institution or venture
capital firm) becoming the beneficial owner, directly or indirectly, of
securities of WFHC representing over: (A) if such Person is a
"Pharmaceutical-related Person" (as defined below), twenty percent (20%) of the
combined voting power of WFHC's then outstanding securities, or (B) if such
Person is not a "Pharmaceutical-related Person", fifty percent (50%) of the
combined voting power of WFHC's then outstanding securities. This termination
right may be exercised by BMS each time there is a change in

                                       7

* Certain material (indicated by an asterisk) has been omitted from this
  document pursuant to a request for confidential treatment.  The omitted
  material has been filed separately with the Securities and Exchange
  Commission.
<PAGE>   8
control, whether or not exercised with respect to an earlier change in control.
Each party shall continue to fulfill its duties hereunder during such 90-day
notice period.

            For purposes of this paragraph 13(d) only,

            "Person" shall have the meaning used in section 13(d) and 14 (d) of
            the Securities Exchange Act of 1934, as amended, and "beneficial
            ownership" shall be determined pursuant to Rule 13d-3 under the
            Securities Exchange Act of 1934, as amended; and

            "Pharmaceutical-related Person" means a Person, or any Affiliate of
            such Person, for whom more than fifty percent (50%) of such
            Person's gross revenues are derived, as applicable, from (i) the
            sale, licensing and/or distribution of drug products (whether
            prescription, generic or over-the counter), nutritional agents and
            medical devices, and (ii) the provision of drug or device management
            services (such as a Pharmaceutical Benefits Management (PBM)
            entity).

                  (e)   The Copromotion Term may be extended as the parties may
mutually agree, it being understood that neither party shall be under any
obligation, express or implied, to do so. In order to be binding upon either
party, any such extension, and the terms governing such extension, must be
evidenced by a written agreement executed by duly authorized representatives of
both parties.

                  (f)   Neither the termination nor expiration of the
Copromotion Term shall release or operate to discharge either party from any
liability or obligation that may have accrued prior to such termination or
expiration. Any termination of the Copromotion Term by a party shall not be an
exclusive remedy, but shall be in addition to any legal or equitable remedies
that may be available to the terminating party.

                  (g)   If the Copromotion Term is terminated by either party
prior to the completion of an Agreement Quarter, WFHC shall be entitled to
receive a pro rata portion of the compensation which it would have been
entitled to receive under Section 11 had the Copromotion Term been in effect
for the entire Agreement Quarter (based on the number of days that WFHC was
responsible for marketing the Product to Covered Physicians in the Territory
during such Agreement Quarter).

                  (h)   Upon the termination or expiration of the Copromotion
Term, WFHC shall promptly cease all of its promotion activities pursuant to
this Agreement, discontinue any use of the Trademark, return to BMS all sales
training, promotional, marketing material, BMS call lists and computer files,
and any remaining Product samples (i.e., not already distributed or destroyed
with destruction certified by WFHC) that may have been supplied to WFHC by BMS
under this Agreement. BMS shall be entitled to promote the Product to all
Covered Physicians thereafter without compensation of obligation to WFHC,
except such compensation obligations as may apply as set forth in Section
11(e). It is understood that the names and addresses of any Covered Physicians
to whom WFHC may have made calls are not considered Confidential Information.

                  (i)   Notwithstanding the expiration or termination of the
Copromotion Term, this Agreement shall be deemed to continue and shall not be
deemed terminated in its entirety and of no further force and effect unless and
until neither party has any further obligation to the other party in

                                       8
<PAGE>   9
accordance with the terms hereof."

                                       9
<PAGE>   10
                        ATTACHMENT 2 TO AMENDMENT NO. 1

Exhibit A of the Copromotion Agreement is replaced with the following:

                                   EXHIBIT A
                          INITIAL EDUCATIONAL PROGRAM

     The Initial Educational Program shall be developed by WFHC and shall
consist of the following elements and timelines:

                      CARDIOVASCULAR PROGRAM WITH OB/GYNS
                            TIME AND EVENT SCHEDULE

<TABLE>
<CAPTION>
          Event                                  Timing                   Comment
          -----                                  ------                   -------
<S>                                              <C>                      <C>
Distinguished Professors' Conference             Jan 8-10, 1999           Attended by 125 of the leadership of
Program: Gateway to Midlife Health-A                                      OB/GYNs. Segment from Dr. Chris Cassel
Better Way.                                                               was included on use of statins to lower
                                                                          cholesterol with pravastatin as choice based on
                                                                          event reduction.

Distinguished Professor Lecture Series           Feb-yr. End 1999         Slide series and script will include section on
Program: Women First HealthCare-A                                         the importance of lowering cholesterol using
Better Way.                                                               statins. A minimum of 50 of these lectures
                                                                          will be held with OB/GYNs across the
                                                                          country. WFHC will consult with BMS as to
                                                                          the selection of the venues and lecturers.

Establishment of a Health Advisory Board for     Feb-April 1999           Health Advisory Board would include
cardiovascular risk management in women.                                  OB/GYNs and cardiologists who have a focus
Program: Managing Cardiovascular Risk-                                    on cardiovascular disease in women. WFHC
A Better Way.                                                             will consult with BMS as to the selection of
                                                                          the Board members.

Health Advisory Board Meeting                    November 1999            Development of guidelines for managing
Program: Managing Cardiovascular Risk-                                    cardiovascular risk in women.
A Better Way.
</TABLE>

                                       10

<PAGE>   11

<TABLE>
<S>                                             <C>                     <C>
Publication of monograph and videotape from           April 1999        Monograph and Videotape would mailed to
Distinguished Professors' Conference.                                   25,000 OB/GYNs. Would include section on
Program: Women First HealthCare - A                                     importance of lowering cholesterol using
Better Way.                                                             statins from Distinguished Professors'
                                                                        Conference.

                      CARDIOVASCULAR PROGRAM WITH OB/GYNS
                        TIME AND EVENT SCHEDULE (CON'T)

                  Event                                Timing                            Comment
                  -----                                ------                            -------

Development of pre-test on managing                  November 1999      Mailed to approximately 25,000 OB/GYNs.
cardiovascular risk in women.                                           Would include detailed answer with
Program: Managing Cardiovascular Risk -                                 references.
A Better Way.

Publication of Consensus Report from Health          November 1999      Would include guidelines for the OB/GYNs in
Advisory Board.                                                         managing cardiovascular disease.
Program: Managing Cardiovascular Risk -
A Better Way.

Development of Lecture Series Kit which              November 1999      Designed to be used to present guidelines in
includes slides, monograph and                                          Consensus Report to OB/GYNs across the
implementation elements.                                                country.
Program: Managing Cardiovascular Risk -
A Better Way.

20 physician meetings                           July 1999 - March 2000  Use of Lecture Series materials with
Program: Managing Cardiovascular Risk -                                 OB/GYNs. WFHC will consult with BMS as
A Better Way.                                                           to venues, timing, and speakers.

Care & Comment Newsletter on                         Q3 or Q4 1999      Will be mailed to 25,000 OB/GYNs.
cardiovascular disease in midlife women.
Program: Gateway to Midlife Health - A
Better Way.

Women-to-Women Meetings                             Throughout 1999     Meetings will include information on
Program: Gateway to Midlife Health -                                    cardiovascular risk in women at midlife.
A Better Way.
</TABLE>

                                       11

<PAGE>   12

<TABLE>
<S>                                                 <C>                     <C>
Support through WFHC                                Throughout 1999         Our Call Center nurses will support the doctor
Midlife HealthLine(TM)                                                      and patient regarding the use of statins to
Program: Gateway to Midlife Health -                                        lower cholesterol.
A Better Way.
</TABLE>

                                       12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00009-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00009-of-00352.parquet"}]]